Recursion Pharmaceuticals Inc
RXRX5.090USD
-0.430-7.79%
Fechamento 08/19, 16:00（ET）Cotações atrasadas em 15 min
2.20BValor de mercado
PerdaP/L TTM
Mais detalhes de Recursion Pharmaceuticals Inc Empresa
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Informações da empresa
Código da empresaRXRX
Nome da EmpresaRecursion Pharmaceuticals Inc
Data de listagemApr 16, 2021
CEODr. Christopher Gibson, Ph.D.
Número de funcionários840
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 16
Endereço41S Rio Grande Street
CidadeSALT LAKE CITY
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal84101
Telefone13852690203
Sitehttps://www.recursion.com/
Código da empresaRXRX
Data de listagemApr 16, 2021
CEODr. Christopher Gibson, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+0.06%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
135.82K
+2.20%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
55.91K
-60.78%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
Director, Chief Research and Development Officer, Chief Commercial Officer
Director, Chief Research and Development Officer, Chief Commercial Officer
14.63K
-20.60%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+0.06%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
135.82K
+2.20%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
55.91K
-60.78%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
9.48M
63.99%
United Kingdom
5.34M
36.01%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
8.43%
ARK Investment Management LLC
7.72%
Baillie Gifford & Co.
5.66%
BlackRock Institutional Trust Company, N.A.
5.60%
SB Global Advisers Ltd
3.43%
Outro
69.16%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
8.43%
ARK Investment Management LLC
7.72%
Baillie Gifford & Co.
5.66%
BlackRock Institutional Trust Company, N.A.
5.60%
SB Global Advisers Ltd
3.43%
Outro
69.16%
Tipos de investidores
Investidores
Proporção
Investment Advisor
43.79%
Investment Advisor/Hedge Fund
10.49%
Venture Capital
7.26%
Sovereign Wealth Fund
3.78%
Individual Investor
2.94%
Hedge Fund
1.96%
Corporation
1.80%
Research Firm
1.73%
Bank and Trust
0.83%
Outro
25.42%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
658
317.16M
74.44%
-11.74M
2025Q1
665
322.62M
81.56%
-7.38M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
2023Q2
358
172.49M
89.73%
-20.74M
2023Q1
345
171.25M
93.19%
-16.02M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
32.23M
8.06%
-1.74M
-5.12%
Mar 31, 2025
ARK Investment Management LLC
34.82M
8.71%
+2.47M
+7.63%
Mar 31, 2025
Baillie Gifford & Co.
24.39M
6.1%
-471.04K
-1.89%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.07M
5.02%
-234.35K
-1.15%
Mar 31, 2025
SB Global Advisers Ltd
14.67M
3.67%
--
--
Mar 31, 2025
Kinnevik AB
13.43M
3.36%
+1.53M
+12.84%
Mar 31, 2025
Mubadala Investment Company PJSC
12.99M
3.25%
--
--
Mar 31, 2025
State Street Global Advisors (US)
13.09M
3.27%
+506.90K
+4.03%
Mar 31, 2025
Novo Holdings A/S
9.67M
2.42%
-449.50K
-4.44%
Mar 31, 2025
MIC Capital Management UK LLP
9.64M
2.41%
-1.00
-0.00%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qua, 6 de ago
Atualizado em: qua, 6 de ago
Nome
Proporção
ARK Genomic Revolution ETF
5.68%
First Trust Nasdaq AI and Robotics ETF
2.38%
ARK Innovation ETF
1.41%
Franklin Genomic Advancements ETF
1.41%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
WisdomTree BioRevolution Fund
0.76%
AXS Green Alpha ETF
0.73%
SPDR S&P Biotech ETF
0.53%
WisdomTree Artificial Intelligence and Innov Fund
0.45%
Direxion Daily S&P Biotech Bull 3X Shares
0.34%
Ver Mais
ARK Genomic Revolution ETF
Proporção5.68%
First Trust Nasdaq AI and Robotics ETF
Proporção2.38%
ARK Innovation ETF
Proporção1.41%
Franklin Genomic Advancements ETF
Proporção1.41%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.88%
WisdomTree BioRevolution Fund
Proporção0.76%
AXS Green Alpha ETF
Proporção0.73%
SPDR S&P Biotech ETF
Proporção0.53%
WisdomTree Artificial Intelligence and Innov Fund
Proporção0.45%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.34%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
